title: Prostate cancer: chemoprevention update 2005.
abstract: BACKGROUND
  If an agent can slow the growth of existing prostate cancer cells, it remains plausible that it may be effective as an adjunct to surgery, radiation or chemotherapy.
  
  
  CONCLUSIONS
  Level-1 evidence will be needed in order to definitively prove the efficacy of agents as chemoprevention strategies for prostate cancer. Currently, only finasteride fulfills this criterion. Two major trials are underway that will assess the role of soy, vitamin E and selenium in prostate cancer prevention.
  
  
  CONCLUSIONS
  Tantalizing prospects for effective chemoprevention of prostate cancer exist. Fortunately, well-conducted randomized trials will allow us to answer many of these questions within the next 2 to 8 years.
authors: Department of Surgery (Urology), University Health Network and University of Toronto, Toronto, Ontario, Canada.
authors: Neil
authors: N
authors: Fleshner
authors: Rami
authors: R
authors: Al Azab
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D002338:Carotenoids / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D000077276:Lycopene; D008297:Male; D008517:Phytotherapy / Q000379:methods; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D012643:Selenium / Q000627:therapeutic use; D013025:Glycine max; D016896:Treatment Outcome; D024502:alpha-Tocopherol / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D004791:Enzyme Inhibitors; D002338:Carotenoids; D024502:alpha-Tocopherol; D012643:Selenium; D000077276:Lycopene